Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5771)
  3. Review (420)
  4. Editorial (194)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (61)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13264)
  2. Center for Hematologic Malignancies (10600)
  3. GSK Faculty (4479)
  4. Adult Leukemia (3669)
  5. Bone Marrow Transplant (2847)
  6. Lymphoma (2702)

More Groups

People
  1. Sergio Giralt (1068)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (668)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (326)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3528)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (329)
  5. Haematologica (291)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3803)
  2. Elsevier Inc. (1529)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1008)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13365)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Confirmatory efficacy and safety evaluation of MB-105, a CD5.CAR T therapy: Multicenter phase 2 study in patients with relapsed/refractory T cell lymphoma (R/R TCL)
    Meeting Abstract

    Iyer, S. P.; Hill, L.; Horwitz, S.; Jain, S.; Poh, C.; Vose, J. M.; Brenner, M. K.; Mamonkin, M.; Hein, S.; Giordano, F.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A phase 2B, open-label multicenter study of tebapivat (AG-946), a potent pyruvate kinase activator, in patients
    Meeting Abstract

    Zeidan, A. M.; Sekeres, M. A.; Al-Samkari, H.; Carraway, H. E.; DeZern, A. E.; Mittelman, M.; Little, M.; Beynon, V.; Dai, X.; Sommakia, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • First results of asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors for patients with chronic myeloid leukemia who do not achieve a deep molecular remission (ALERT CML) from the H Jean Khoury Cure CML Consortium (HJKC3)
    Meeting Abstract

    Cortes, J. E.; Mauro, M. J.; Visotcky, A.; Tantravahi, S. K.; Thompson, J. E.; Yang, J.; Baim, A.; Gao, Y.; Maldonado-Schmidt, S.; Olig, C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Cardinal: A phase I, multicenter, open-label, dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of TERN-701 in chronic myeloid leukemia
    Meeting Abstract

    Jabbour, E.; Rea, D.; Cortes, J. E.; Hochhaus, A.; Hughes, T. P.; Kim, D. W.; Kantarjian, H. M.; Holes, L.; Kuriakose, E. T.; Mauro, M. J.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes of CAR T-cell therapies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma who received prior treatment with mosunetuzumab
    Meeting Abstract

    Braun, A.; Schuster, S. J.; Nastoupil, L.; Bartlett, N. L.; Shadman, M.; Kumar, A.; Tzachanis, D.; Chihara, D.; Wu, M.; Wei, M. C.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of progression-free survival of relapsed or refractory follicular lymphoma patients in a single-arm trial of tazemetostat with a real-world external control arm
    Meeting Abstract

    Salles, G.; Leonard, J. P.; Morschhauser, F.; Crowley, A.; Sosinsky, A. Z.; Lieb, C.; Zeldow, B.; Harton, J.; Wang, S.; Boyer, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Prospective feasibility trial of pharmacokinetic directed melphalan for lymphoma patients undergoing autologous hematopoietic cell transplantation
    Meeting Abstract

    Hughes, C. F. M.; Lin, A.; Bromberg, M.; Devlin, S. M.; Saldia, A.; Engstler, D. E.; Hanley, D. M.; Aremu, Y.; Donach, M.; Hoover, E.; more...
    Blood (2024)

    Fulltext@MSK | Save